POLIOVIRUS VACCINE LIVE ORAL TRIVALENT HUMAN SOLUTION Canada - English - Health Canada

poliovirus vaccine live oral trivalent human solution

aventis pasteur limited - poliovirus vaccine live orl-trival human type-1; poliovirus vaccine live orl-trival human type-2; poliovirus vaccine live orl-trival human type-3 - solution - 1000000unit; 100000unit; 150000unit - poliovirus vaccine live orl-trival human type-1 1000000unit; poliovirus vaccine live orl-trival human type-2 100000unit; poliovirus vaccine live orl-trival human type-3 150000unit - vaccines

POLIOVIRUS VACCINE LIVE ORAL TRIVALENT SUSPENSION Canada - English - Health Canada

poliovirus vaccine live oral trivalent suspension

aventis pasteur limited - poliovirus vaccine live orl-trival human type-1; poliovirus vaccine live orl-trival human type-2; poliovirus vaccine live orl-trival human type-3 - suspension - 1000000unit; 100000unit; 300000unit - poliovirus vaccine live orl-trival human type-1 1000000unit; poliovirus vaccine live orl-trival human type-2 100000unit; poliovirus vaccine live orl-trival human type-3 300000unit - vaccines

ADENOVIRUS TYPE 4 AND TYPE 7 VACCINE, LIVE kit United States - English - NLM (National Library of Medicine)

adenovirus type 4 and type 7 vaccine, live kit

teva women's health, inc. - human adenovirus e serotype 4 strain cl-68578 (unii: fkd3duk39i) (human adenovirus e serotype 4 strain cl-68578 - unii:fkd3duk39i) - human adenovirus e serotype 4 strain cl-68578 32000 [tcid_50] - adenovirus type 4 and type 7 vaccine, live, oral is a vaccine indicated for active immunization for the prevention of febrile acute respiratory disease caused by adenovirus type 4 and type 7. adenovirus type 4 and type 7 vaccine, live, oral is approved for use in military populations 17 through 50 years of age. adenovirus type 4 and type 7 vaccine, live, oral should not be administered to pregnant females [see pregnancy (8.1)] . it is not known whether adenovirus type 4 and type 7 vaccine, live, oral can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. naturally occurring infection with adenoviruses has been associated with fetal harm. pregnancy should be avoided for 6 weeks following receipt of vaccine. severe allergic reaction (e.g., anaphylaxis) to any component of adenovirus type 4 and type 7 vaccine, live, oral is a contraindication [see description (11)]. adenovirus type 4 and type 7 vaccine, live, oral should not be administered to individuals incapable of swa

VARIVAX REFRIGERATED varicella virus vaccine live powder for  injection vial with prefilled diluent syringe Australia - English - Department of Health (Therapeutic Goods Administration)

varivax refrigerated varicella virus vaccine live powder for injection vial with prefilled diluent syringe

merck sharp & dohme (australia) pty ltd - live varicella vaccine, quantity: 2700 pfu/ml - injection, powder for - excipient ingredients: monobasic potassium phosphate; potassium chloride; hydrolysed gelatin; sodium chloride; dibasic sodium phosphate; urea; sucrose; monosodium glutamate monohydrate - varivax refrigerated is indicated for vaccination against varicella in healthy individuals 12 months of age and older.,see the australian immunisation handbook for vaccination recommendations and schedule.,groups who would particularly benefit from vaccination include:,? non-immune adults, especially those in at-risk occupations such as health-care workers, teachers and workers in children?s day-care centres.,? non-immune parents of young children.,? non-immune household contacts, both adults and children, of immunocompromised patients with no history of disease.

Pandemic influenza vaccine H5N1 AstraZeneca (previously Pandemic influenza vaccine H5N1 Medimmune) European Union - English - EMA (European Medicines Agency)

pandemic influenza vaccine h5n1 astrazeneca (previously pandemic influenza vaccine h5n1 medimmune)

astrazeneca ab - reassortant influenza virus (live attenuated) of the following strain: a/vietnam/1203/2004 (h5n1) strain - influenza, human - vaccines - prophylaxis of influenza in an officially declared pandemic situation in children and adolescents from 12 months to less than 18 years of age.pandemic influenza vaccine h5n1 astrazeneca should be used in accordance with official guidance

VARIVAX REFRIGERATED varicella virus vaccine live powder for  injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

varivax refrigerated varicella virus vaccine live powder for injection vial

merck sharp & dohme (australia) pty ltd - live varicella vaccine, quantity: 2700 pfu/ml - injection, powder for - excipient ingredients: monosodium glutamate monohydrate; urea; sodium chloride; potassium chloride; sucrose; hydrolysed gelatin; monobasic potassium phosphate; dibasic sodium phosphate - varivax refrigerated is indicated for vaccination against varicella in healthy individuals 12 months of age and older.,see the australian immunisation handbook for vaccination recommendations and schedule.,groups who would particularly benefit from vaccination include:,? non-immune adults, especially those in at-risk occupations such as health-care workers, teachers and workers in children?s day-care centres.,? non-immune parents of young children.,? non-immune household contacts, both adults and children, of immunocompromised patients with no history of disease.

VARIVAX REFRIGERATED varicella virus vaccine live powder for injection vial with sterile diluent vial Australia - English - Department of Health (Therapeutic Goods Administration)

varivax refrigerated varicella virus vaccine live powder for injection vial with sterile diluent vial

merck sharp & dohme (australia) pty ltd - live varicella vaccine, quantity: 2700 pfu/ml - diluent, not applicable - excipient ingredients: water for injections - varivax refrigerated is indicated for vaccination against varicella in healthy individuals 12 months of age and older.,see the australian immunisation handbook for vaccination recommendations and schedule.,groups who would particularly benefit from vaccination include:,? non-immune adults, especially those in at-risk occupations such as health-care workers, teachers and workers in children?s day-care centres.,? non-immune parents of young children.,? non-immune household contacts, both adults and children, of immunocompromised patients with no history of disease.

ROTATEQ rotavirus vaccine live oral pentavalent pre-filled dosing tube Australia - English - Department of Health (Therapeutic Goods Administration)

rotateq rotavirus vaccine live oral pentavalent pre-filled dosing tube

merck sharp & dohme (australia) pty ltd - rotavirus g2 human-bovine reassortant, quantity: 1400000 infectious unit/ml; rotavirus g3 human-bovine reassortant, quantity: 1100000 infectious unit/ml; rotavirus g1 human-bovine reassortant, quantity: 1100000 infectious unit/ml; rotavirus g4 human-bovine reassortant, quantity: 1000000 infectious unit/ml; rotavirus p1 [8] human-bovine reassortant, quantity: 1150000 infectious unit/ml - oral liquid - excipient ingredients: polysorbate 80; sucrose; sodium citrate dihydrate; sodium hydroxide; monobasic sodium phosphate; glucose monohydrate; sodium ascorbate; sodium chloride; ammonium metavanadate; calcium chloride dihydrate; cupric sulfate pentahydrate; ferric nitrate nonahydrate; ferrous sulfate heptahydrate; magnesium chloride hexahydrate; dried magnesium sulfate; manganese sulfate tetrahydrate; ammonium molybdate; potassium chloride; sodium acetate; sodium bicarbonate; dibasic sodium phosphate; zinc sulfate heptahydrate; alanine; arginine hydrochloride; asparagine; aspartic acid; cysteine hydrochloride; cystine dihydrochloride; glutamic acid; glycine; histidine hydrochloride monohydrate; hydroxyproline; isoleucine; leucine; lysine hydrochloride; methionine; phenylalanine; proline; serine; threonine; tryptophan; tyrosine disodium; valine; biotin; ergocalciferol; choline chloride; folic acid; inositol; menadione; nicotinamide; nicotinic acid; aminobenzoic acid; calcium pantothenate; pyridoxal hydrochloride; pyridoxine hydrochloride; retinol acetate; riboflavine; dl-alpha-tocopheryl phosphate disodium; thiamine hydrochloride; cyanocobalamin; adenine sulfate dihydrate; adenosine triphosphate disodium; adenosine monophosphate; cholesterol; deoxyribose; glutathione; guanine hydrochloride; sodium hypoxanthine; linoleic acid; alpha lipoic acid; phenolsulfonphthalein; putrescine dihydrochloride; sodium pyruvate; ribose; thymidine; thymine; uracil; sodium xanthine; monoethanolamine; 2-mercaptoethanol; adenosine; uridine; cytidine; guanosine; dexamethasone; epidermal growth factor; hydrocortisone; insulin; alprostadil; liothyronine; ascorbic acid; magnesium sulfate heptahydrate; monobasic sodium phosphate monohydrate; zinc sulfate; arginine; cysteine; cystine; histidine; lysine; tyrosine; adenosine triphosphate; guanine; putrescine - rotateq is indicated for the prevention of rotavirus gastroenteritis (see clinical trials).

IMOVAX POLIO, suspension for injection in multidose vial Poliomyelitis vaccine (inactivated) Malta - English - Medicines Authority

imovax polio, suspension for injection in multidose vial poliomyelitis vaccine (inactivated)

sanofi pasteur 14 espace henry vallée , 69007 lyon, france - poliovirus, inactivated, type, mahoney strain, mef, saukett strain - suspension for injection - poliovirus (inactivated) type 1 (mahoney strain) 8 dagu poliovirus (inactivated) type 2 (mef-1 strain) 40 dagu poliovirus (inactivated) type 3 (saukett strain) 40 dagu - vaccines